Drug Trial Radar · NCT04299893
Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Nov 30, 2020
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Bernardino Clavo, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Servicio Canario de Salud; Instituto de Salud Carlos III; Red de Investigación en Servicios de Salud en Enfermedades Crónicas; Fundación DISA, Spain; Fundación Española del Dolor (FED); Council of Gran Canaria
- First posted
- Mar 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy
Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Pain, Neuropathic
- Pain Syndrome
Interventions
OzoneDrug
Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
OxygenDrug
Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in "Average pain" according to the Brief Pain Inventory-Short Form (BPI-SF) (at the end of ozone therapy)Time frame: 16 weeks
- Direct Hospital Cost (at the end of ozone therapy)Time frame: 16 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Complejo Hospitalario Materno Insular
Las Palmas de Gran Canaria, Las Palmas, Spain · Recruiting
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Las Palmas, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.